MX429190B - Composiciones y métodos de oximetazolina para el tratamiento de trastornos oculares - Google Patents

Composiciones y métodos de oximetazolina para el tratamiento de trastornos oculares

Info

Publication number
MX429190B
MX429190B MX2021013516A MX2021013516A MX429190B MX 429190 B MX429190 B MX 429190B MX 2021013516 A MX2021013516 A MX 2021013516A MX 2021013516 A MX2021013516 A MX 2021013516A MX 429190 B MX429190 B MX 429190B
Authority
MX
Mexico
Prior art keywords
oxymetazoline
compositions
methods
eye disorders
treatment
Prior art date
Application number
MX2021013516A
Other languages
English (en)
Other versions
MX2021013516A (es
Inventor
David Jacobs
Tina Devries
Original Assignee
Rvl Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rvl Pharmaceuticals Inc filed Critical Rvl Pharmaceuticals Inc
Publication of MX2021013516A publication Critical patent/MX2021013516A/es
Publication of MX429190B publication Critical patent/MX429190B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A61J1/10—Bag-type containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención está dirigida a composiciones que comprenden oximetazolina y métodos para estabilizar composiciones de oximetazolina para almacenamiento a largo plazo. La presente invención también está dirigida a composiciones que comprenden oximetazolina y métodos para tratar diversos trastornos oculares relacionados con párpados caídos, tales como ptosis, en un sujeto que comprende administrar al sujeto composiciones que comprenden oximetazolina.
MX2021013516A 2019-05-06 2020-05-05 Composiciones y métodos de oximetazolina para el tratamiento de trastornos oculares MX429190B (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962843819P 2019-05-06 2019-05-06
US201962844069P 2019-05-06 2019-05-06
US16/716,014 US10799481B1 (en) 2019-05-06 2019-12-16 Compositions and methods for treating ocular disorders
US16/715,998 US10814001B1 (en) 2019-05-06 2019-12-16 Oxymetazoline compositions
PCT/US2020/031425 WO2020227260A1 (en) 2019-05-06 2020-05-05 Oxymetazoline compositions and methods for treating ocular disorders

Publications (2)

Publication Number Publication Date
MX2021013516A MX2021013516A (es) 2022-01-24
MX429190B true MX429190B (es) 2025-11-13

Family

ID=72750169

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021013516A MX429190B (es) 2019-05-06 2020-05-05 Composiciones y métodos de oximetazolina para el tratamiento de trastornos oculares

Country Status (16)

Country Link
US (11) US10814001B1 (es)
EP (1) EP3965737A1 (es)
JP (3) JP7141420B2 (es)
KR (3) KR102410503B1 (es)
CN (2) CN117045596A (es)
AU (1) AU2020268329B2 (es)
BR (1) BR112021022404A2 (es)
CL (1) CL2021002918A1 (es)
CO (1) CO2021015265A2 (es)
IL (1) IL287831A (es)
MA (1) MA55895A (es)
MX (1) MX429190B (es)
PE (1) PE20220384A1 (es)
SG (1) SG11202112272TA (es)
WO (1) WO2020227260A1 (es)
ZA (2) ZA202108950B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120225918A1 (en) * 2011-03-03 2012-09-06 Voom, Llc Compositions and Methods for Non-Surgical Treatment of Ptosis
US10814001B1 (en) * 2019-05-06 2020-10-27 Rvl Pharmaceuticals, Inc. Oxymetazoline compositions
WO2022187306A1 (en) 2021-03-03 2022-09-09 Voom, Llc Compositions and methods for treatment of blepharitis
WO2023079427A1 (en) * 2021-11-03 2023-05-11 Avaca Pharma Private Limited Ophthalmic compositions and methods thereof

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE51421B1 (en) 1980-08-01 1986-12-24 Smith & Nephew Ass Ophthalmic compositions containing triamterene
US5459133A (en) 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
US5888493A (en) 1996-12-05 1999-03-30 Sawaya; Assad S. Ophthalmic aqueous gel formulation and related methods
JP2002249445A (ja) 2000-12-19 2002-09-06 Ophtecs Corp 眼科用液剤組成物
US6806364B2 (en) 2002-07-29 2004-10-19 Ast Products, Inc. Ophthalmic compositions
ES2397574T3 (es) * 2002-07-30 2013-03-08 Omeros Corporation Procedimiento y soluciones de irrigación oftalmológica
DE10337186A1 (de) 2003-08-13 2005-03-17 Merck Patent Gmbh Wässrige Wirkstoff-Lösung
US7812049B2 (en) 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
JP2006131628A (ja) * 2004-10-08 2006-05-25 Rohto Pharmaceut Co Ltd オキシメタゾリン含有水性組成物
US8758816B2 (en) 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
KR20140083056A (ko) 2006-03-17 2014-07-03 존슨 앤드 존슨 비젼 케어, 인코포레이티드 산화에 불안정한 성분을 포함하는 안정화된 안과용 조성물
US8685439B2 (en) 2006-04-26 2014-04-01 Aciex Therapeutics, Inc. Method for the treatment and prevention of eyelid swelling
WO2008070185A2 (en) 2006-12-06 2008-06-12 The Trustees Of Columbia University In The City Of New York Method of stabilizing human eye tissue by reaction with nitrite and related agents such as nitro compounds
MX2010005012A (es) 2007-11-08 2010-06-23 Aciex Therapeutics Inc Composiciones para el tratamieno y prevencion de inflamacion de los parpados que comprenden un ingrediente osmoticamente activo y un vasocosntrictor.
BRPI0821647A2 (pt) * 2007-12-21 2015-06-16 Schering Plough Healthcare Realce da fotosestabillização de oximetazolina
RU2481842C2 (ru) * 2008-03-11 2013-05-20 Алькон Рисерч, Лтд. Низковязкие высокофлокулированные суспензии триамцинолона ацетонида для интравитреальных инъекций
CA2764477A1 (en) * 2009-06-05 2010-12-09 Aciex Therapeutics, Inc. Ophthalmic formulations, methods of manufacture, and methods of using same
US20120082625A1 (en) 2010-09-28 2012-04-05 Michael Graeber Combination treatment for rosacea
CN104758921A (zh) * 2010-11-08 2015-07-08 希尔洛有限公司 缓冲的眼用组合物以及使用其的方法
DK2645993T3 (en) 2010-12-03 2017-02-13 Allergan Inc Pharmaceutical cream compositions comprising oxymetazoline
US20120225918A1 (en) 2011-03-03 2012-09-06 Voom, Llc Compositions and Methods for Non-Surgical Treatment of Ptosis
RU2605290C2 (ru) 2011-04-26 2016-12-20 Рдд Фарма Лтд. Оксиметазолин для лечения аноректальных нарушений
EP2854781A4 (en) 2012-05-25 2016-04-13 Xlear Inc XYLITOL-BASED ANTIMUKOSAL COMPOSITIONS AND ASSOCIATED METHODS AND COMPOSITIONS
UA119324C2 (uk) 2013-04-02 2019-06-10 Теміс Медікер Лімітед Композиції фармацевтично активних речовин, що містять моноетиловий ефір діетиленгліколю або інші алкільні похідні
CN111465309B (zh) 2013-09-18 2021-11-30 迈康尼股份公司 用于组件的改进的存储和处理的方法、系统和设备
CA2951725C (en) 2014-06-11 2022-06-07 Allergan, Inc. Stabilized oxymetazoline formulations and their uses
US11052094B2 (en) 2015-05-29 2021-07-06 Sydnexis, Inc. D2O stabilized pharmaceutical formulations
US20170312335A1 (en) * 2015-12-30 2017-11-02 Lubris Llc Topical use of prg4 for treatment of allergy and symptoms of inflammation
CN115006537A (zh) 2016-01-26 2022-09-06 利维申制药有限公司 α-肾上腺素能药剂的组合物和用途
CN105997856A (zh) * 2016-06-24 2016-10-12 魏威 盐酸羟甲唑啉滴眼液及其制备方法
US11246816B2 (en) 2016-06-30 2022-02-15 The Procter And Gamble Company Shampoo compositions comprising a chelant
US10814001B1 (en) * 2019-05-06 2020-10-27 Rvl Pharmaceuticals, Inc. Oxymetazoline compositions

Also Published As

Publication number Publication date
US20210137889A1 (en) 2021-05-13
CN111888326A (zh) 2020-11-06
US11103482B2 (en) 2021-08-31
US10898573B1 (en) 2021-01-26
EP3965737A1 (en) 2022-03-16
JP2020183373A (ja) 2020-11-12
CN111888326B (zh) 2023-07-21
US12605363B2 (en) 2026-04-21
US11311515B2 (en) 2022-04-26
JP7141420B2 (ja) 2022-09-22
US20220273621A1 (en) 2022-09-01
US10799481B1 (en) 2020-10-13
US10940138B2 (en) 2021-03-09
US20210015795A1 (en) 2021-01-21
JP2025065198A (ja) 2025-04-17
KR102663319B1 (ko) 2024-05-03
NZ782902A (en) 2024-09-27
ZA202108950B (en) 2023-10-25
CL2021002918A1 (es) 2022-08-19
US20210212992A1 (en) 2021-07-15
CO2021015265A2 (es) 2022-02-28
PE20220384A1 (es) 2022-03-18
KR20220084264A (ko) 2022-06-21
US20220257566A1 (en) 2022-08-18
KR102410503B1 (ko) 2022-06-17
CN117045596A (zh) 2023-11-14
ZA202212328B (en) 2025-03-26
US10814001B1 (en) 2020-10-27
IL287831A (en) 2022-01-01
US20200353083A1 (en) 2020-11-12
MX2021013516A (es) 2022-01-24
US20210386711A1 (en) 2021-12-16
US12648930B2 (en) 2026-06-09
SG11202112272TA (en) 2021-12-30
CA3139443A1 (en) 2020-11-12
KR20200128629A (ko) 2020-11-16
US20210023222A1 (en) 2021-01-28
MA55895A (fr) 2022-03-16
KR102859351B1 (ko) 2025-09-12
US11701343B2 (en) 2023-07-18
US20230355587A1 (en) 2023-11-09
AU2020268329A1 (en) 2022-01-06
AU2020268329B2 (en) 2026-01-15
KR20240060580A (ko) 2024-05-08
JP2021191802A (ja) 2021-12-16
JP7705326B2 (ja) 2025-07-09
US11541036B2 (en) 2023-01-03
BR112021022404A2 (pt) 2022-01-18
US11324722B2 (en) 2022-05-10
WO2020227260A1 (en) 2020-11-12
US20240033250A1 (en) 2024-02-01